In order to finance the Company and accelerate the work towards an exit, primarily through continued investments in the migraine market with the support of latest study results, the Board of Directors has resolved to propose the Rights Issue. If fully subscribed, the Rights Issue is estimated to raise approximately 51.3 MSEK to Chordate Medical before costs related to the issue.
Terms and conditions of the Rights Issue
The Board of Directors’ proposal to the extraordinary general meeting includes that the Rights Issue be carried out in accordance with the main conditions set out below.
Timetable for the Rights Issue
13 December 2022 Extraordinary general meeting
16 December 2022 Last day of trading including the right to receive subscription rights
19 December 2022 First day of trading excluding the right to receive subscription rights
20 December 2022 Record date for participation in the Rights Issue
21 December 2022 Estimated date for publication of Prospectus
22 December 2022 – 9 January 2023 Subscription period.
22 December 2022 – 3 January 2023 Trading in subscription rights.
22 December 2022 Trading in paid subscription shares (Sw. “BTA”) until the Rights Issue is registered by the Swedish Companies Registration Office (Sw. “Bolagsverket”).
11 January 2023 Expected publication of subscription result in the Rights Issue.